What is the 13F Pro Quality Score for SVA?

13F Pro ranks SINOVAC BIOTECH LTD (SVA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SVA's current score at https://13fpro.ai/company/SVA (free sign-up required for the full ranking).

Which hedge funds own the most SVA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of SVA include ORBIMED ADVISORS, Vivo Capital,, Neumann Advisory Hong Kong Ltd. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/SVA as soon as new 13F filings post.

Where does 13F Pro source SVA data?

All SINOVAC BIOTECH LTD fundamentals and ownership data come directly from SEC EDGAR. SINOVAC BIOTECH LTD files with the SEC under CIK 1084201. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SVA in?

SINOVAC BIOTECH LTD (SVA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SVA research updated on 13F Pro?

SVA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

SINOVAC BIOTECH LTD(SVA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1084201 SVA stock profile & AI dashboard →

InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro Quality Score

23.1/100

Rank #2,733 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why SVA Scores 23/100

exact factor attribution · 2026-09-11

SVA's composite is driven by shareholder dilution, held back by free cash flow and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Shareholder dilution

+2.1 pts

93th pct

Earnings growth

-1.0 pts

30th pct

Institutional flow

-1.3 pts

24th pct

Capital efficiency

-2.3 pts

27th pct

Scale

-3.0 pts

30th pct

Revenue growth

-4.0 pts

30th pct

Earnings quality

-4.9 pts

1th pct

Profitability

-5.9 pts

11th pct

Free cash flow

-6.7 pts

6th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

SVA Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for SINOVAC BIOTECH LTD (SVA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SVA at 23.1/100 on a 32-signal composite quality model, placing it at rank #2,733 of 2,961 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (FY 2025), SINOVAC BIOTECH LTD reports quarterly revenue of $386.0M, net income of $-198.8M, free cash flow of $-561.1M. Top institutional holders of SVA by reported 13-F value include ORBIMED ADVISORS, Vivo Capital, Neumann Advisory Hong Kong Ltd, based on the most recent SEC filings. SVA trades on the Nasdaq exchange and files with the SEC under CIK 1084201. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SVA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SINOVAC BIOTECH LTD directly from SEC EDGAR. SINOVAC BIOTECH LTD's 13F Pro composite quality score has ranged between 23 and 24 since 2026, currently 23.1 — a stable long-term trajectory across 14 quarterly and live scoring snapshots.

Revenue

FY 2025

$386.0M

Net Income

FY 2025

$-198.8M

Free Cash Flow

FY 2025

$-561.1M

ROIC

FY 2025

-9.9%

D/E Ratio

FY 2025

0.11

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+6.8% YoY

$386.0MFY 2025

FY22 $1.47BFY23 $470.2MFY24 $361.4MFY25 $386.0M

Net Income

—FY 2025

FY22 $14.5MFY23 $-13.5MFY24 —FY25 —

Operating Income

+3.0% YoY

$-490.1MFY 2025

FY22 $-509.0MFY23 $-714.0MFY24 $-505.5MFY25 $-490.1M

EPS (Diluted)

-165.4% YoY

$-0.83FY 2025

FY22 $0.20FY23 $-0.19FY24 $1.27FY25 $-0.83

Total Assets

-30.8% YoY

$8.54BFY 2025

FY22 $14.03BFY23 $13.61BFY24 $12.34BFY25 $8.54B

Total Debt

+31.7% YoY

$494.9MFY 2025

FY22 $11.8MFY23 $253.9MFY24 $375.8MFY25 $494.9M

Op. Cash Flow

-800.3% YoY

$-512.2MFY 2025

FY22 $-798.1MFY23 $138.6MFY24 $-56.9MFY25 $-512.2M

Free Cash Flow

-267.1% YoY

$-561.1MFY 2025

FY22 $-1.11BFY23 $-17.5MFY24 $-152.9MFY25 $-561.1M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$386.0M +6.8%	$361.4M -23.1%	$470.2M -68.1%	$1.47B -92.4%	$19.37B +3692.5%	$510.6M
Net Income	—	—	$-13.5M -193.3%	$14.5M -99.8%	$8.12B +7259.1%	$110.4M
Operating Income	$-490.1M +3.0%	$-505.5M +29.2%	$-714.0M -40.3%	$-509.0M -102.9%	$17.62B +8070.1%	$215.6M
EPS (Diluted)	$-0.83 -165.4%	$1.27 +768.4%	$-0.19 -195.0%	$0.20 -99.8%	$113.44 +11594.8%	$0.97
Total Assets	$8.54B -30.8%	$12.34B -9.4%	$13.61B -3.0%	$14.03B -16.3%	$16.76B +781.4%	$1.90B
Total Debt	$494.9M +31.7%	$375.8M +48.0%	$253.9M +2050.7%	$11.8M -25.1%	$15.8M -55.1%	$35.1M
Operating Cash Flow	$-512.2M -800.3%	$-56.9M -141.0%	$138.6M +117.4%	$-798.1M -105.2%	$15.32B +3096.7%	$479.3M
Free Cash Flow	$-561.1M -267.1%	$-152.9M -772.4%	$-17.5M +98.4%	$-1.11B -107.6%	$14.73B +2972.7%	$479.3M

AI Insight: SVA Financial Trends

Equity base collapsed 46% year-over-year while debt nearly doubled, signaling severe balance-sheet deterioration.

• Total debt surged from $376M in Q4 2024 to $495M in Q4 2025, a 32% increase.

• Shareholder equity plummeted from $8.3B in Q4 2024 to $4.4B in Q4 2025, a 46% decline.

• Debt-to-equity ratio deteriorated sharply to 11.2% in Q4 2025 from 4.6% in Q4 2024.

⚠ Equity has contracted nearly 53% from peak of $9.3B in Q4 2021; underlying cause of erosion unclear from balance-sheet data alone.

⚠ Missing revenue, net income, and operating cash flow data prevents assessment of operational health driving balance-sheet changes.

AI Insight: SVA Ratio Trends

Leverage has doubled to 0.11 D/E by end-2025, the highest level in seven years, signaling a shift in capital structure.

• Debt-to-equity ratio rose from 0.05 in Q4 2024 to 0.11 in Q4 2025, matching TTM 0.11.

• D/E levels remain well below 2018–2020 peaks (0.03–0.05 range), indicating balance sheet still conservative historically.

⚠ D/E doubled in one year; monitor whether debt accumulation reflects strategic investment or operational stress.

Get alerted when SVA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for SINOVAC BIOTECH LTD including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SVA

ORBIMED ADVISORS LLC
$184.5M2,718,735 sh
Vivo Capital, LLC
$38.2M5,903,000 sh
Neumann Advisory Hong Kong Ltd
$2.0M315,586 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$106.3K16,430 sh
MORGAN STANLEY
$59.2K9,146 sh
WELLS FARGO & COMPANY/MN
$29.6K4,580 sh
UBS Group AG
$16.0K2,479 sh
HARBOUR INVESTMENTS, INC.
$503.0078 sh
Horizon Investments, LLC
$336.0052 sh
OSAIC HOLDINGS, INC.
$0.001,001 sh

Fund	Value	Shares
ORBIMED ADVISORS LLC	$184.5M	2,718,735
Vivo Capital, LLC	$38.2M	5,903,000
Neumann Advisory Hong Kong Ltd	$2.0M	315,586
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$106.3K	16,430
MORGAN STANLEY	$59.2K	9,146
WELLS FARGO & COMPANY/MN	$29.6K	4,580
UBS Group AG	$16.0K	2,479
HARBOUR INVESTMENTS, INC.	$503.00	78
Horizon Investments, LLC	$336.00	52
OSAIC HOLDINGS, INC.	$0.00	1,001

Companies Similar to SVA

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

VALN

Valneva SE

AI score

Very similar · 1 shared holders

Vivo Capital, LLC

RVP

RETRACTABLE TECHNOLOGIES INC

AI score

Similar quality profile

CLLS

Cellectis S.A.

AI score

Similar quality profile

TRIB

TRINITY BIOTECH PLC

AI score

Similar quality profile

INCR

Intercure Ltd.

AI score

Similar quality profile

NBTX

Nanobiotix S.A.

AI score

Similar quality profile

IMMP

IMMUTEP Ltd

AI score

Similar quality profile

MTEX

MANNATECH INC

AI score

Similar quality profile

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SVA on your watchlist

Track score changes the day SINOVAC BIOTECH LTD files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SVA a good stock to buy?

13F Pro's AI-powered analysis of SINOVAC BIOTECH LTD (SVA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SVA are available on the SVA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SVA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SVA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of SINOVAC BIOTECH LTD's investment landscape.